Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801. Clz and MK-801 in KO1A mice

Neuropharmacology

Volumn 59, Issue 1-2, 2010, Pages 112-120

  Scorza, María Cecilia ^a   Castañé, Anna ^b,c   Bortolozzi, Analía ^b,c   Artigas, Francesc ^b,c  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

5 HT1A receptor knockout (KO1A) mice; Atypical antipsychotics; Locomotor activity; NMDA antagonists

Indexed keywords

CLOZAPINE; DIZOCILPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 ANTAGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENOTYPE; HYPERACTIVITY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; STEREOTYPY; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; MALE; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; RESTLESSNESS;

ANIMALS; ATAXIA; CLOZAPINE; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERAZINES; PSYCHOMOTOR AGITATION; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 77953285824     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.04.012     Document Type: Article

References (65)

1. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex 2004, 14:281-299.
2. Andine P., Widermark N., Axelsson R., Nyberg G., Ofsson U., Martensson E., Sandberg M. Characterization of MK-801-induced behaviour as a putative rat model of psychosis. J. Pharmacol. Exp. Ther. 1999, 290:1393-1408.
3. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63-101.
4. 1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABA(A) receptors. J. Neurosci. 2004, 24(28):6343-6351.
5. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J. Psychopharmacol. 2001, 15:37-46.
6. 1A agonist properties. Neuropsychopharmacology 2005, 31(9):1869-1879.
7. 1A receptor knockout mice. J. Neurochem. 2004, 88:1373-1379.
8. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996, 14:87-96.
9. Cao B.J., Rodgers R.J. Dopamine D4 receptor and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze. Eur. J. Pharmacol. 1997, 335:117-125.
10. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990, 13:272-276.
11. 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist-than dopamine agonist-induced hyperactivity in mice. J. Neural Transm. 1999, 106:123-129.
12. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 1993, 112:S55-S59.
13. 1A receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex. Psychopharmacology 2008, 200:281-290.
14. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 2003, 166(3):234-240.
15. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
16. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-d-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 1993, 265:1001-1010.
17. Deustch S.I., Rosse R.B., Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin. Neuropharmacol. 1997, 20:375-384.
18. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 2005, 25:10831-10843.
19. Ebenezer I.S., Surujbally A. The effects of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) on food intake in non-deprived C57BL6 mice. Eur. J. Pharmacol. 2007, 559:184-188.
20. Geyer M.A., Ellenbroek B. Animal behaviour models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1071-1079.
21. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
22. Gleason S.D., Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 1997, 129:79-84.
23. 1A agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur. J. Pharmacol. 1995, 287:179-184.
24. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76:1521-1531.
25. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:8467-8472.
26. Javitt D.C., Zukkin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
27. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
28. Kargieman L., Santana N., Mengod G., Celada P., Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14843-14848.
29. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
30. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl.) 2003, 169:215-233.
31. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 1999, 288:774-781.
32. Leriche L., Schwartz J.-C., Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 2003, 45:174-181.
33. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
34. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166:152-163.
35. 1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 1993, 242:99-104.
36. Maj J., Rogoz Z., Skuza G., Wedzony K. The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J. Neural Transm. 1996, 103:131-146.
37. 2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251(1):238-246.
38. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
39. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?. Behav. Brain Res. 2008, 195(1):98-102.
40. Millan M.J., Brocco M., Gobert A., Schreiber R., Dekeyne A. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4 fluorophenyl) ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 1998, 288(3):1002-1014.
41. 1A receptors. J. Pharmacol. Exp. Ther. 2000, 295:853-861.
42. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
43. Moghaddam B., Jackson M.E. Glutamatergic animal models of schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:131-137.
44. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviours related to schizophrenia. Cell 1999, 98:427-436.
45. Nilsson M., Waters S., Waters N., Carlsson A., Carlsson M.L. A behavioural pattern analysis of hypoglutamatergic mice-effect of four different antipsychotics agents. J. Neural Transm. 2001, 108:1181-1196.
46. Nilsson M., Markinhuhta K.R., Carlsson M.L. Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:521-530.
47. 1A receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10734-10739.
48. 3H] prazosin. Brain Res. Protoc. 2001, 8:191-198.
49. 1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 1992, 12:440-453.
50. 1A receptor activation. Eur. J. Pharmacol. 1997, 338:R3-R5.
51. Roth B.L., Sheffler D., Potkin S.G. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'?. Clin. Neurosci. Res. 2003, 3:108-117.
52. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 2004, 14:1100-1109.
53. Schotte A., Janssen P.F.M., Megens A.A.H.P., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993, 631:191-202.
54. Scorza M.C., Meikle M.N., Hill X.L., Richeri A., Lorenzo D., Artigas F. Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine. Int. J. Neuropsychopharmacol. 2008, 11:519-532.
55. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
56. Spanos L.J., Yamamoto B.K. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-) MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol. Biochem. Behav. 1989, 32:835-840.
57. 1A receptors in classical fear conditioning in C57BL/6J mice. J. Neurosci. 2000, 20:8515-8527.
58. Svensson T.H. Preclinical effects of conventional and atypical antipsychotic drugs: defining the mechanisms of action. Clin. Neurosci. Res. 2003, 3:34-46.
59. 14C]methyl-l-tryptophan. Eur. Neuropsychopharmacol. 2001, 11:193-202.
60. 1A receptor knockout mouse as a genetic model of anxiety. Eur. J. Pharmacol. 2003, 463(1-3):177-184.
61. Väisänen J., Ihalainen J., Tanila H., Castrén E. Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia. Cell. Mol. Neurobiol. 2004, 24:769-780.
62. Wadenberg M.L. Serotonergic mechanism in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 1996, 20:325-339.
63. 1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 2000, 23:547-559.
64. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., Zhao G., Jin M., Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology 2005, 177:256-263.
65. Youn J., Misane I., Eriksson T.M., Millan M.J., Ogren S.O., Verhage M., Stiedl O. Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities. Neuropharmacology 2009, 57(5-6):567-576.